Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 12.7% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,791 shares of the medical research company’s stock after purchasing an additional 202 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Charles River Laboratories International were worth $181,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in Charles River Laboratories International by 4.7% in the 1st quarter. Vanguard Group Inc. now owns 5,033,513 shares of the medical research company’s stock worth $452,764,000 after purchasing an additional 225,563 shares during the period. BlackRock Inc. boosted its stake in Charles River Laboratories International by 12,573.1% in the 1st quarter. BlackRock Inc. now owns 3,845,643 shares of the medical research company’s stock worth $345,915,000 after purchasing an additional 3,815,298 shares during the period. FMR LLC boosted its stake in Charles River Laboratories International by 39.7% in the 1st quarter. FMR LLC now owns 2,488,113 shares of the medical research company’s stock worth $223,806,000 after purchasing an additional 707,612 shares during the period. Ariel Investments LLC boosted its stake in Charles River Laboratories International by 30.7% in the 1st quarter. Ariel Investments LLC now owns 2,060,420 shares of the medical research company’s stock worth $185,335,000 after purchasing an additional 483,564 shares during the period. Finally, State Street Corp boosted its stake in Charles River Laboratories International by 1.1% in the 1st quarter. State Street Corp now owns 1,239,943 shares of the medical research company’s stock worth $111,539,000 after purchasing an additional 13,759 shares during the period. 95.37% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “Charles River Laboratories International, Inc. (CRL) Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank” was originally reported by Daily Political and is the property of of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US & international copyright & trademark law. The legal version of this news story can be read at https://www.dailypolitical.com/2017/09/18/charles-river-laboratories-international-inc-crl-shares-bought-by-zurcher-kantonalbank-zurich-cantonalbank.html.

Charles River Laboratories International, Inc. (NYSE CRL) opened at 106.02 on Monday. Charles River Laboratories International, Inc. has a 1-year low of $67.20 and a 1-year high of $109.59. The stock’s 50 day moving average is $103.01 and its 200-day moving average is $95.28. The firm has a market capitalization of $5.05 billion, a P/E ratio of 27.94 and a beta of 0.99.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, August 9th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.22 by $0.07. The firm had revenue of $469.13 million during the quarter, compared to analysts’ expectations of $458.25 million. Charles River Laboratories International had a net margin of 10.13% and a return on equity of 27.02%. The business’s revenue was up 8.1% on a year-over-year basis. During the same period last year, the company earned $1.20 earnings per share. Analysts forecast that Charles River Laboratories International, Inc. will post $5.10 EPS for the current year.

A number of equities analysts recently weighed in on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $120.00 target price on shares of Charles River Laboratories International in a research note on Tuesday, September 12th. Robert W. Baird reaffirmed a “buy” rating and issued a $114.00 target price on shares of Charles River Laboratories International in a research note on Friday, September 1st. BidaskClub raised shares of Charles River Laboratories International from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 22nd. Zacks Investment Research lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Barclays PLC reaffirmed a “hold” rating and issued a $102.00 target price on shares of Charles River Laboratories International in a research note on Wednesday, July 19th. Five investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company. Charles River Laboratories International currently has an average rating of “Buy” and a consensus price target of $98.55.

In other news, Chairman James C. Foster sold 43,154 shares of Charles River Laboratories International stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of $100.00, for a total transaction of $4,315,400.00. Following the completion of the transaction, the chairman now directly owns 361,178 shares in the company, valued at $36,117,800. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William D. Barbo sold 4,000 shares of Charles River Laboratories International stock in a transaction dated Thursday, August 17th. The shares were sold at an average price of $99.91, for a total transaction of $399,640.00. Following the transaction, the insider now owns 20,424 shares of the company’s stock, valued at $2,040,561.84. The disclosure for this sale can be found here. Insiders have sold 79,982 shares of company stock valued at $7,951,868 over the last quarter. Corporate insiders own 2.20% of the company’s stock.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.